loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Savolitinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942477/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-ESMO-Congress-2024-and-the-2024-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib

    29 Mar 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168216&sid=2

    PHARMABIZ
    29 Mar 2024
    Share Share
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2853678/0/en/HUTCHMED-Announces-Savolitinib-sNDA-Accepted-in-China-for-Treatment-Na%C3%AFve-or-Previously-Treated-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib
    HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib

    12 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/12/2741334/0/en/HUTCHMED-Highlights-Presentation-of-Results-from-the-Phase-IIIb-Trial-of-Savolitinib-at-the-2023-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    12 Sep 2023
    Share Share
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer

    29 Aug 2023

    // PRESS RELEASE

    https://www.hutch-med.com/savolitinib-china-breakthrough-therapy-designation-for-gastric-cancer/

    PRESS RELEASE
    29 Aug 2023
    Share Share
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer

    28 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/29/2733012/0/en/HUTCHMED-Receives-Breakthrough-Therapy-Designation-in-China-for-Savolitinib-for-Gastric-Cancer.html

    GLOBENEWSWIRE
    28 Aug 2023
    Share Share